erlotinib hydrochloride has been researched along with Hospital-Acquired Condition in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kenzaka, T; Miyoshi, K; Nakaji, H | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
2 other study(ies) available for erlotinib hydrochloride and Hospital-Acquired Condition
| Article | Year |
|---|---|
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure | 2018 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |